E2F7 promotes ESCC progression and cisplatin resistance through transcriptional activation of DVL3 and the Wnt signaling pathway
E2F7 promotes ESCC progression and cisplatin resistance by transcriptionally activating DVL3 and activating the Wnt signaling pathway. Targeting the E2F7-DVL3 axis may provide a promising therapeutic strategy for ESCC treatment.
Authors
- Tongxin Xu (ORCID: https://orcid.org/0000-0002-5418-3020)
- Zhaoyang Yan (ORCID: https://orcid.org/0000-0001-7392-2493)
- Liying Chen (ORCID: https://orcid.org/0000-0003-0990-7648)
- Xiaoxu Li (ORCID: https://orcid.org/0000-0002-3778-3964)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hebei University of Chinese Medicine (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1186/s12957-025-04113-5
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00